Stratec Valuation

Is SBSD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SBSD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SBSD (€32.6) is trading below our estimate of fair value (€62.34)

Significantly Below Fair Value: SBSD is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SBSD?

Key metric: As SBSD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SBSD. This is calculated by dividing SBSD's market cap by their current earnings.
What is SBSD's PE Ratio?
PE Ratio33.4x
Earnings€10.01m
Market Cap€334.90m

Price to Earnings Ratio vs Peers

How does SBSD's PE Ratio compare to its peers?

The above table shows the PE ratio for SBSD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28.6x
NIOX NIOX Group
22.6x17.1%UK£249.1m
EKF EKF Diagnostics Holdings
24xn/aUK£114.6m
SN. Smith & Nephew
35.3x22.5%UK£8.6b
TSTL Tristel
32.3x17.5%UK£209.8m
SBSD Stratec
33.4x25.4%€334.9m

Price-To-Earnings vs Peers: SBSD is expensive based on its Price-To-Earnings Ratio (33.4x) compared to the peer average (28.6x).


Price to Earnings Ratio vs Industry

How does SBSD's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No. of Companies9PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SBSD is expensive based on its Price-To-Earnings Ratio (33.4x) compared to the European Medical Equipment industry average (29.7x).


Price to Earnings Ratio vs Fair Ratio

What is SBSD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SBSD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio33.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate SBSD's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SBSD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€41.00
0%
14.5%€50.00€31.00n/a6
Nov ’25n/a
€41.00
0%
14.5%€50.00€31.00n/a6
Oct ’25n/a
€43.83
0%
9.2%€50.00€40.00n/a6
Sep ’25n/a
€42.33
0%
7.0%€47.00€40.00n/a6
Aug ’25n/a
€42.33
0%
7.0%€47.00€40.00n/a6
Jul ’25n/a
€42.33
0%
7.0%€47.00€40.00n/a6
Jun ’25n/a
€42.33
0%
7.0%€47.00€40.00n/a6
May ’25n/a
€43.83
0%
12.7%€55.00€40.00n/a6
Apr ’25€39.10
€49.00
+25.3%
14.0%€58.00€40.00n/a6
Mar ’25n/a
€49.00
0%
14.0%€58.00€40.00n/a6
Feb ’25n/a
€49.00
0%
14.0%€58.00€40.00n/a6
Jan ’25n/a
€52.17
0%
8.5%€58.00€44.00n/a6
Dec ’24n/a
€54.00
0%
4.7%€58.00€50.00n/a6
Nov ’24n/a
€54.50
0%
5.1%€58.00€50.00n/a6
Oct ’24n/a
€57.00
0%
6.2%€62.00€52.00n/a6
Sep ’24n/a
€58.67
0%
4.0%€62.00€55.00n/a6
Aug ’24n/a
€59.33
0%
4.4%€62.00€55.00n/a6
Jul ’24n/a
€74.67
0%
11.4%€87.00€62.00n/a6
Jun ’24n/a
€73.67
0%
11.0%€87.00€62.00n/a6
May ’24n/a
€72.83
0%
12.2%€87.00€62.00n/a6
Apr ’24€64.30
€75.33
+17.2%
9.9%€87.00€63.00€39.106
Mar ’24€76.20
€102.00
+33.9%
15.0%€125.00€82.00n/a6
Feb ’24n/a
€102.00
0%
15.0%€125.00€82.00n/a6
Jan ’24n/a
€102.00
0%
15.0%€125.00€82.00n/a6
Dec ’23€86.30
€102.00
+18.2%
15.0%€125.00€82.00n/a6
Nov ’23n/a
€103.83
0%
14.0%€125.00€82.00n/a6

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies